ArticleFrontiers in microbiology2025
Effects of gut microbiota dysbiosis on the metabolism and pharmacokinetics of losartan in rats: from endogenous to ceftriaxone-induced dysbiosis.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Heart-Gut Axis in Heart Failure: The Role of Next-Generation Pharmacological Therapies.International journal of molecular sciences · 2026Review
- Gut microbiota as a driver of variable antihypertensive drug response: A narrative review.Gut microbes reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gut microbiota plays a key role in drug metabolism. While gut microbiota dysbiosis is known to contribute to hypertension pathogenesis, its impact on drug metabolism remains poorly considered. Clinically, the pharmacokinetic variability of losartan potassium is partially attributed to genetic polymorphisms of the CYP2C9 enzyme and structural variations in AGTR1. However, the potential role of gut microbiota dysbiosis in regulating losartan pharmacokinetics remains unclear. Methods: In the present study, we assessed the effect of gut microbiota dysbiosis on the metabolism and pharmacokinetics of losartan in two different rat models: spontaneously hypertensive rats (SHRs) with endogenous gut microbiota dysbiosis and rats with ceftriaxone (CRO)-induced gut microbiota dysbiosis combined with Results: The results showed that the intestinal flora from SHRs led to a more significant degradation of losartan than that from Wistar Kyoto rats (WKYs) Conclusion: This study highlights that gut microbiota dysbiosis diminishes losartan bioavailability, providing evidence that gut microbiota contributes to the pharmacokinetic variability of losartan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.